• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Insulet (PODD), Why Is It Back In The Spotlight?

    Simply Wall St·09/02/2026 17:25:03
    Listen to the news

    Insulet (PODD) is back in focus after a federal securities class action lawsuit alleged the company misled investors about its manufacturing controls, following earlier voluntary Medical Device Corrections tied to specific Omnipod product lots.

    At a share price of US$148.38, Insulet has seen a mixed run, with a 7 day share price return of 3.73% and a 90 day share price return of 3.55%. This is set against a sharper 30 day share price decline of 10.26% and a year to date share price decline of 47.55%.

    Compare how the market is treating Insulet compared with other businesses facing regulatory or legal pressure by scanning our curated list of 74 resilient stocks with low risk scores today.

    Insulet still runs a large, revenue generating diabetes business, yet the stock is down sharply this year and now trades below some analyst targets. The key issue for investors is whether that gap reflects value or fresh risk.

    Most Popular Narrative: 37% Undervalued

    Against Insulet's last close of $148.38, the most followed narrative anchors on a fair value of about $235.54, using a 7.53% discount rate and explicit assumptions about future revenue, earnings and margins.

    Rapidly rising adoption of Omnipod 5 in both the U.S. and international markets, driven by strong clinical evidence, ease of use, and superior integration with the latest glucose sensors, is positioning Insulet to capture a disproportionately large share of the expanding global diabetes device market, supporting outsized top-line revenue growth for several years.

    Read the complete narrative. Read the complete narrative.

    If you want to understand why this narrative points to a fair value well above Insulet's current share price, focus on how it pairs multi year revenue expansion with rising profit margins and a lower future earnings multiple that still supports the higher valuation.

    Result: Fair Value of $235.54 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, Insulet's reliance on the Omnipod platform and ongoing class action and recall issues could still undermine confidence in the claim that it is 37% undervalued.

    Find out about the key risks to this Insulet narrative.

    Another View: Insulet Through a P/E Lens

    The SWS DCF model points to Insulet trading at a discount to estimated future cash flows, but the P/E picture is less one sided. At 27.4x earnings, the stock is slightly above the US Medical Equipment industry at 27x, yet below peers at 36.6x and a fair ratio of 31.2x. Is that a margin of safety or a sign of lingering risk?

    See what the numbers say about this price — find out in our valuation breakdown.

    NasdaqGS:PODD P/E Ratio as at Sep 2026
    NasdaqGS:PODD P/E Ratio as at Sep 2026

    Next Steps

    With sentiment on Insulet split between risk and opportunity, now is a good time to review the underlying data yourself and move quickly. To see exactly what investors view as the bright spots, take a closer look at the 3 key rewards.

    Looking for more investment ideas beyond Insulet?

    If Insulet has your attention, now is the moment to broaden your watchlist with other clear, data driven ideas from the Simply Wall Street Screener.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.